Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266240 · ClinicalTrials.gov registry record · Phase 2
A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
- 20
- Study locations
NCT00266240: Completed Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Hoffmann-La Roche.
NCT00266240 is a Phase 2 study of Diabetes Mellitus, Type 2 that has completed, run by Hoffmann-La Roche. The registered enrollment target is 267 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00266240, a Phase 2 study of Diabetes Mellitus, Type 2, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GK Activator (2)
Study Locations (20)
California
- - Chula Vista
- - Spring Valley
- - West Hills
North Carolina
- - Fayetteville
- - Statesville
- - Winston-Salem
Pennsylvania
- - Beaver
- - Tipton
Arizona
- - Tucson
Arkansas
- - Pine Bluff
Florida
- - Hollywood
Georgia
- - Atlanta
New York
- - Binghamton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00266240 record still lists
NCT00266240 is an interventional study that assigns participants to a tested intervention. The registered 267 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00266240 names 20 study sites across 15 states, led by California, North Carolina, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00266240 about?
NCT00266240 is a clinical study titled "A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus". This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.
What is the current status of trial NCT00266240?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2005-11. Estimated completion is 2007-05.
What conditions does trial NCT00266240 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT00266240?
The interventions under investigation include: Placebo (DRUG), GK Activator (2) (DRUG).
Who is sponsoring clinical trial NCT00266240?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00266240 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00266240's enrollment target sits among peer trials
267 133rd of 348 higher than 216 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04997109 · 267 participants · NA
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
- NCT05355701 · 267 participants · Phase 1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
- NCT06203509 · 267 participants · NA
Improving Care Transitions for Medicaid Insured Individuals With Co-occurring Serious Mental Illness
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia